Transforming outcomes in advanced lung cancer: immunotherapy in unselected patients

Immunotherapeutic agents are increasingly becoming incorporated into clinical practice; however, there is still much to learn, including their optimal combinations, sequencing and usage. In this inter... Author: VJOncology Added: 04/20/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts

Related Links:

This study analyzed the current literature on the treatment of neoplastic pericardial effusion to provide advice and guidance for clinical treatment. Surgical treatments include pericardial puncture, extension of catheter drainage, pericardial window, and surgical pericardiotomy. Each surgical procedure has a corresponding indication, and the best treatment is selected according to the patient's specific conditions. Systemic chemotherapy is effective in lymphoma and small cell lung cancer that are sensitive to chemotherapeutic drugs. Although pericardial injection of drugs is effective for pericardial tamponade and re...
Source: Herz - Category: Cardiology Tags: Herz Source Type: research
Publication date: Available online 11 July 2019Source: American Journal of Kidney DiseasesAuthor(s): Roman Shingarev, Ilya G. GlezermanImmunologic control of malignancy has long been recognized as an important determinant of disease progression. Recent advances in immunology have led to the focus on several mechanisms that can be targeted to achieve tumor suppression. In particular, checkpoint inhibition has evolved in less than a decade to become one of the most important strategies in cancer therapy, with a meaningful improvement in patient survival. Six agents have been approved for clinical use to date and many more ar...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
A new study examined whether stereotactic body radiotherapy prior to pembrolizumab improved response rate in lung cancer patients.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Lung cancer remains a significant health care burden, accounting for 11.6% (2.094 million) of all cancer cases and 18.4% (1.8 million) of cancer related deaths [1]. With advances in targeted therapeutics and immunotherapy agents [2], five-year survival rates are improving with recent SEER data indicating a rate of 19.4% [3]. However, chemotherapy is still widely used, with more recent trials combining traditional chemotherapy with newer agents [4]. Cisplatin, cis-Diamineplatinum (II) dichloride, is a common chemotherapeutic agent used in the treatment of advanced NSCLC [5 –9], and is currently one of the most effecti...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
We report on a case of pseudoprogression, which was presented as intestinal perforation after pembrolizumab immunotherapy for NSCLC. A-54-year-old man with stage IV NSCLC received pembrolizumab therapy. The patient was admitted to our hospital because of acute abdominal pain and the computed tomography scan revealed diffuse wall thickening of the small bowel with free intraperitoneal air. Intestinal perforation was suspected and surgical resection was performed. Histological evaluation of the resected specimen showed infiltrated lymphocytes positive for CD3, CD8 with necrotic tumor cells, suggestive of an immune reaction. ...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
Authors: Levy BP, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Parisi M Abstract Background: Commonly used first-line (1L) chemotherapies for patients with advanced squamous-cell lung cancer (scc) include gemcitabine-platinum (gp), nab-paclitaxel-carboplatin (nabpc), and sb-paclitaxel-carboplatin (sbpc) regimens. However, no head-to-head trials have compared those treatments. In the present study, we compared the efficacy of 1L gp, nabpc, and sbpc in patients with scc and in patients with scc who subsequently received second-line (2L) immunotherapy. Methods: Medical records of patients who initiated th...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
(University of Pennsylvania School of Medicine) Treating metastatic non-small cell lung cancer (NSCLC) patients with the immunotherapy drug pembrolizumab after they've completed locally ablative therapy almost tripled the median progression-free survival (PFS) compared to the historical average.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Authors: Sandler JE, D'Aiello A, Halmos B Abstract The management of advanced non-small cell lung cancer (NSCLC) has been revolutionized in recent years with the introduction of biomarker-targeted molecular therapies and immune checkpoint inhibitors. In contrast, since adjuvant chemotherapy was first established twenty years ago as the standard of care, little has changed for resected early-stage (IB-IIIA) patients for whom the potential for cure is greatest. In this manuscript we will review recently presented data as well as ongoing/planned studies in this arena. So far, investigative efforts have yielded mixed r...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Conclusion The entire tumor burden evaluated by 18F-FDG PET/CT can be predictive of response to immunotherapy in patients with metastatic lung cancer. A large prospective multicenter trial is warranted to definitively assess the usefulness of 18F-FDG PET/CT as a predictive biomarker of response to immunotherapy.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Abstract Among cancers, lung cancer is the most morbidity and mortality disease that is remaining the fatalist. Generally, there are multiple treatment procedures for lung cancer, such as surgery, immunotherapy, radiotherapy and chemotherapy. There is, therefore, an urgent need for more specified and efficient methods for treatment of lung cancer such as RNAi, which in combination with traditional therapies could silence genes that are involved in the drug resistance. These genes may either be motivators of apoptosis inhibition, EMT and DNA repair system promoters or a member of intracellular signaling pathways, s...
Source: Gene - Category: Genetics & Stem Cells Authors: Tags: Gene Source Type: research
More News: Cancer | Cancer & Oncology | Immunotherapy | Learning | Lung Cancer | Universities & Medical Training